On Thursday, May 22, 2017, The Pediatric Advisory Committee met to evaluate the use of indwelling central access devices in Sarepta Therapeutics ESSENCE study of exons-45 and 53 skipping compounds.
In 2014, upon request of the Food and Drug Administration, Jett Foundation collected and quantified Exondys 51 patient and caregiver experience data to provide the agency with color and context surrounding the benefits that patients and their families with experience on drug were seeing in the home setting.
Fox News 13 in Tampa covers Jett Giving success story!
Jett Foundation is delighted to announce that yesterday we gifted Florida residents, Austin Wilcher and his Dad Joe, with a brand new handicap accessible vehicle as part of the Jett Giving Fund.
This morning, PTC Therapeutics announced their plans to launch EMFLAZA (deflazacort) in the coming weeks for a list price of $35,000 per 25 kilograms.
Aidan Braswell, a 12-year-old with Duchenne, and his family seek to raise half of the funds for a $47,244 handicap accessible van through donations on their First Giving Page.
Ethan Pyles loves to hang out with friends, root for his favorite sports team, swim in the pool, and play with his dog Axel. However, unlike other teens his age, Ethan has never ridden a bike around the neighborhood with his friends, played on a sports team with other kids, or even chased his dog Axel around the backyard.
On Sunday, April 2, 2017 Jett Foundation hosted the Tennessee Educational Roundtable in Nashville. Companies developing drugs for the treatment of Duchenne attended and presented to families in Nashville.